Antigenics Oncophage
Executive Summary
Antigenics expects Oncophage (HSPPC-96) Phase III melanoma trial enrollment to be completed by the end of 2004 after FDA lifts partial clinical hold on cancer vaccine. FDA requested additional data on "product characterization issues" (1"The Pink Sheet" Sept. 8, 2003, p. 28). Enrollment for the kidney trial is almost complete...